NEW: We are building a Digital Health Class where we want to teach people about this fast-growing industry. Click here for more information.

MAP and Intent Solutions to assess medication compliance in patients with addiction

The partnership will launch with a pilot program as early as March of this year wherein a number of patients whose risk for relapse is continuously measured by MAP's technology will be provided a TAD™ biometric pill dispensation device. The device will send real-time data to MAP's platform when a patient takes their medication, or fails to do so. With this information, MAP can inform the appropriate members of collaborative care networks if a patient is overusing their medication, or failing to take their medication at all. This information is then leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other modes of mitigating recidivism and costly treatment episodes.


"The number one factor in improving outcomes is early intervention. Putting the TAD™ into the hands of people recovering from addiction who are prescribed medication will greatly enable MAP to better inform treatment providers, family members, and insurance carriers who are at high risk for relapse and readmission resulting from the lack of medication compliance."
Jacob Levenson, CEO of MAP Health Management
"We are excited to partner with MAP and empower their ecosystem with our TAD™ device. We know that our product has great efficacy for those with Substance Use Disorder and MAP knows how to leverage our device to improve outcomes for all of the stakeholders."
Sam Zamarripa, President and Director of Intent Solutions
Links: Source

Leave a Reply

Help us launch Digital Health Class, the site where we teach people about this fast-growing industry. Click here for more information.